Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease

Revista Espanola de Enfermedades Digestivas

Volumn 104, Issue 9, 2012, Pages 468-472

  Barreiro de Acosta, Manuel ^a   Lorenzo, Aurelio ^a   Enrique Dominguez Munoz J ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

Adalimumab; Anti TNF; Extraintestinal manifestations

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FAMILY HISTORY; FEMALE; HUMAN; MALE; OPEN STUDY; PERIPHERAL ARTHRITIS; PHENOTYPE; PYODERMA GANGRENOSUM; REMISSION; SACROILIITIS; SEX DIFFERENCE; SMOKING HABIT; TREATMENT DURATION; UVEITIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; COMPLICATION; ERYTHEMA NODOSUM; MIDDLE AGED; PROSPECTIVE STUDY; SCLERITIS; SMOKING; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS; CROHN DISEASE; ERYTHEMA NODOSUM; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYODERMA GANGRENOSUM; SCLERITIS; SMOKING; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; YOUNG ADULT;

EID: 84869040735     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082012000900004     Document Type: Article

References (30)

1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N, The prevalence of extraintestinal diseases in inflammatory bowel disease: a populationbased study. Am J Gastroenterol 2001;96:1116-22.
2. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401-12.
3. Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003;9:2300-7.
4. Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010;42:97-114.
5. Rankin GB, Watts HD, Melnyk CS, Kelley ML, Jr. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-20.
6. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004;10:207-14.
7. Salvarani C, Vlachonikolis IG, van der Heijde DM, Fornaciari G, Macchioni P, Beltrami M, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001;36:1307-13.
8. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996;23:29-34.
9. Barreiro-de Acosta M, Dominguez-Munoz JE, Nunez-Pardo de Vera MC, Lozano-Leon A, Lorenzo A, Pena S. Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations. Eur J Gastroenterol Hepatol 2007;19:73-8.
10. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010;4:63-101.
11. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1424-9.
12. Repiso A, Alcántara M, Muñoz-Rosas C, Rodríguez-Merlo R, Pérez-Grueso MJ, Carrobles JM, et al. Extraintestinal manifestations of Crohn's disease: prevalence and related factors. Rev Esp Enferm Dig 2006;98:510-7.
13. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31:307-27.
14. De Vos M. Joint involvement associated with inflammatory bowel disease. Dig Dis 2009;27:511-5.
15. Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009;15:2449-55.
16. Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-83.
17. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.
18. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
19. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38.
20. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
21. Lofberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE. Inflamm Bowel Dis 2012;18:1-9.
22. López Palacios N, Mendoza JL, Taxonera C, Lana R, Fuentes Ferrer M, Díaz-Rubio M. Adalimumab induction and maintenance therapy for Crohn's disease. An open-label study. Rev Esp Enferm Dig 2008;100:676-81.
23. Cordero Ruiz P, Castro Márquez C, Méndez Rufián V, Castro Laria L, Caunedo Álvarez A, Romero Vázquez J, et al. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series. Rev Esp Enferm Dig 2011;103:294-8.
24. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53.
25. Triantafillidis JK, Mantzaris G, Karagiannis J, Papavasilliou E, Papatheodoridis G, Fouskas J, et al. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab. Rev Med Chir Soc Med Nat Iasi 2010;114:85-90.
26. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
27. Zold E, Nagy A, Devenyi K, Zeher M, Barta Z. Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone. World J Gastroenterol 2009; 15:2293-5.
28. Herfarth H, Obermeier F, Andus T, Rogler G, Nikolaus S, Kuehbacher T, et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 2002;97:2688-90.
29. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, place-bo-controlled trial. Arthritis Rheum 2006;54:2136-46.
30. Levine JB, Lukawski-Trubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Am 1995; 24:633-46